Paula S Koekkoek1, Geert Jan Biessels2, Minke Kooistra3, Jolien Janssen3, L Jaap Kappelle2, Guy E H M Rutten3. 1. Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, the Netherlands. Electronic address: p.s.koekkoek-3@umcutrecht.nl. 2. Department of Neurology, Brain Center Rudolf Magnus, University Medical Center, Utrecht, the Netherlands. 3. Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, the Netherlands.
Abstract
AIMS: Type 2 diabetes (T2DM) is associated with cognitive impairment. We examined whether undiagnosed cognitive impairment in T2DM-patients is associated with a reduced health status and depressive symptoms. METHODS: In an observational study, 225 T2DM-patients aged ≥70years were examined at their homes and (some of them) at a memory clinic for undiagnosed cognitive impairment (dementia or mild cognitive impairment [MCI], defined according to internationally accepted criteria). Questionnaires assessing health status (SF-36, EQ-5D, EQ-VAS) and depressive symptoms (CES-D) were filled out. Health status and depressive symptoms were compared between patients with and without cognitive impairment. RESULTS: Patients with cognitive impairment (n=57) showed significantly lower scores on the physical and mental summary scores of the SF-36 than patients with normal cognition (difference: 3.5 (95%-CI 0.7-6.3, p=0.02, effect size 0.41) and 2.9 (95%-CI 0.3-5.6; p=0.03, effect size 0.37). EQ-5D index and EQ-VAS scores were significantly lower in patients with cognitive impairment. Depression (CES-D≥16) occurred almost twice as often in patients with cognitive impairment (RR 1.8; 95%-CI: 1.1-3.0). CONCLUSIONS: Undiagnosed cognitive impairment in T2DM-patients is associated with a reduced health status and more depressive symptoms. Detection of cognitive impairment in T2DM-patients identifies a vulnerable patient group that could benefit from tailored treatment and care.
AIMS: Type 2 diabetes (T2DM) is associated with cognitive impairment. We examined whether undiagnosed cognitive impairment in T2DM-patients is associated with a reduced health status and depressive symptoms. METHODS: In an observational study, 225 T2DM-patients aged ≥70years were examined at their homes and (some of them) at a memory clinic for undiagnosed cognitive impairment (dementia or mild cognitive impairment [MCI], defined according to internationally accepted criteria). Questionnaires assessing health status (SF-36, EQ-5D, EQ-VAS) and depressive symptoms (CES-D) were filled out. Health status and depressive symptoms were compared between patients with and without cognitive impairment. RESULTS:Patients with cognitive impairment (n=57) showed significantly lower scores on the physical and mental summary scores of the SF-36 than patients with normal cognition (difference: 3.5 (95%-CI 0.7-6.3, p=0.02, effect size 0.41) and 2.9 (95%-CI 0.3-5.6; p=0.03, effect size 0.37). EQ-5D index and EQ-VAS scores were significantly lower in patients with cognitive impairment. Depression (CES-D≥16) occurred almost twice as often in patients with cognitive impairment (RR 1.8; 95%-CI: 1.1-3.0). CONCLUSIONS: Undiagnosed cognitive impairment in T2DM-patients is associated with a reduced health status and more depressive symptoms. Detection of cognitive impairment in T2DM-patients identifies a vulnerable patient group that could benefit from tailored treatment and care.
Authors: Jolien Janssen; Paula S Koekkoek; Geert Jan Biessels; L Jaap Kappelle; Guy E H M Rutten Journal: Diabetol Metab Syndr Date: 2019-02-22 Impact factor: 3.320
Authors: Quinlan D Buchlak; Nazanin Esmaili; Christine Bennett; Yi Yuen Wang; James King; Tony Goldschlager Journal: PLoS One Date: 2022-07-27 Impact factor: 3.752
Authors: Rebecca M Lovett; Laura M Curtis; Stephen D Persell; James W Griffith; Derin Cobia; Alex Federman; Michael S Wolf Journal: Patient Educ Couns Date: 2020-03-12
Authors: Jessie N Zurita-Cruz; Leticia Manuel-Apolinar; María Luisa Arellano-Flores; Alejandro Gutierrez-Gonzalez; Alma Gloria Najera-Ahumada; Nelly Cisneros-González Journal: Health Qual Life Outcomes Date: 2018-05-15 Impact factor: 3.186